- Home
- NCNA vs PTIX Comparison
NCNA vs PTIX Comparison
Compare NCNA & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- PTIX
- Stock Information
- Founded
- NCNA 1997
- PTIX 1994
- Country
- NCNA United Kingdom
- PTIX United States
- Employees
- NCNA N/A
- PTIX N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- PTIX Health Care
- Exchange
- NCNA Nasdaq
- PTIX Nasdaq
- Market Cap
- NCNA 4.3M
- PTIX 3.7M
- IPO Year
- NCNA 2017
- PTIX 2016
- Fundamental
- Price
- NCNA $1.14
- PTIX $0.44
- Analyst Decision
- NCNA Buy
- PTIX
- Analyst Count
- NCNA 2
- PTIX 0
- Target Price
- NCNA $25.00
- PTIX N/A
- AVG Volume (30 Days)
- NCNA 238.3K
- PTIX 377.2K
- Earning Date
- NCNA 11-25-2024
- PTIX 11-14-2024
- Dividend Yield
- NCNA N/A
- PTIX N/A
- EPS Growth
- NCNA N/A
- PTIX N/A
- EPS
- NCNA N/A
- PTIX N/A
- Revenue
- NCNA N/A
- PTIX N/A
- Revenue This Year
- NCNA N/A
- PTIX N/A
- Revenue Next Year
- NCNA N/A
- PTIX N/A
- P/E Ratio
- NCNA N/A
- PTIX N/A
- Revenue Growth
- NCNA N/A
- PTIX N/A
- 52 Week Low
- NCNA $0.96
- PTIX $0.43
- 52 Week High
- NCNA $19.40
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- NCNA 43.15
- PTIX 39.26
- Support Level
- NCNA $0.96
- PTIX $0.43
- Resistance Level
- NCNA $1.37
- PTIX $0.52
- Average True Range (ATR)
- NCNA 0.15
- PTIX 0.05
- MACD
- NCNA -0.00
- PTIX -0.01
- Stochastic Oscillator
- NCNA 26.09
- PTIX 6.74
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.